Update on biomarkers for amyloid pathology in Alzheimer’s disease

Written by Nicholas J Ashton, Michael Schöll, Kerstin Heurling, Eleni Gkanatsiou, Erik Portelius, Kina Höglund, Gunnar Brinkmalm, Abdul Hye, Kaj Blennow & Henrik Zetterberg

At the center of Alzheimer’s disease (AD) pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers...

To view the full article, please register now for access

It's completely free